Sponsored
Bansi Nagji discusses the shifting science behind rare and orphan drug development, including what it takes for therapies to succeed well beyond launch.
Bansi Nagji, CEO, PANTHERx Rare
Advertisement
Articles by Bansi Nagji, CEO, PANTHERx Rare
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
The Changing Reality of Pharmaceutical Commercialization in a Cold Chain-Driven Market
2
Vertex to Acquire Crinetics Pharmaceuticals for $10 Billion
3
Reshoring Pharma and Biotech Manufacturing Ahead of This Summer’s Tariff Deadlines: Q&A with Ryan Last
4
Novartis to Acquire Myricx Bio for $1.1 Billion
5